18 Sep 2025 | 3 Mins Read
Sun Pharma upgraded by Citi with 35% price gain potential
Flipitmoney
Citi reiterated its 'Buy' rating on Sun Pharmaceutical Industries, adding the stock to its Pan Asia Focus List. The brokerage forecasts a 35% upside with a price target of ₹2,180 per share, driven by innovation revenues increasing to $3.2 billion by FY30. This contradicts BofA's downgrade to 'Underperform' earlier.